Abcellera Biologics Inc. current report, 15 June 2023

Full document

AbCellera Biologics Inc. 8-K Summary

Business Context and Reporting Period

This Form 8-K reports on the Annual Meeting of Shareholders held by AbCellera Biologics Inc. on June 15, 2023. The record date for the meeting was April 17, 2023, with 288,653,194 common shares outstanding and entitled to vote.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.

Material Changes and Voting Results

Shareholders voted on three proposals, all of which were approved:

  • Proposal 1 (Director Election): John S. Montalbano, CFA, and Peter Thiel were elected as Class III directors for a three-year term.
  • Proposal 2 (Auditor Ratification): KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
  • Proposal 3 (Say-on-Pay): Shareholders approved the compensation of named executive officers on a non-binding advisory basis.

Voting Breakdown

Nominee/Proposal For Against Abstain
John S. Montalbano, CFA 167,257,682 10,997,867 165,946
Peter Thiel 131,151,160 47,033,189 237,146
Ratify KPMG LLP 200,983,540 299,897 186,386
Say-on-Pay 159,440,607 18,625,842 355,046

Broker non-votes totaled 23,048,328 common shares for both Proposal 1 and Proposal 3.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.

Investor Verification Checklist

  • Verify the terms of the newly elected directors (John S. Montalbano and Peter Thiel) and their specific roles.
  • Review the Definitive Proxy Statement filed on April 28, 2023, for detailed descriptions of the proposals and executive compensation.
  • Confirm the impact of the significant "Against" votes for Peter Thiel (approximately 36% of votes cast) on future board dynamics.
  • Check subsequent filings for the company's financial performance, as this 8-K contains no financial data.